Mymetics Corporation Stock Other OTC
Equities
MYMX
US62856A1025
Biotechnology & Medical Research
Sales 2021 | 430K 459K | Sales 2022 | 1.03M 1.1M | Capitalization | 8.51M 9.1M |
---|---|---|---|---|---|
Net income 2021 | -4M -4.27M | Net income 2022 | -4M -4.27M | EV / Sales 2021 | 177 x |
Net Debt 2021 | 67.1M 71.68M | Net Debt 2022 | 71.68M 76.57M | EV / Sales 2022 | 78 x |
P/E ratio 2021 |
-1.86
x | P/E ratio 2022 |
-1.77
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 09-06-30 | |
Mario Amacker
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Staehelin
BRD | Director/Board Member | 76 | 07-07-01 |
Ulrich Burkhard
BRD | Director/Board Member | 63 | 12-03-22 |
Marcel B. Rüegg
BRD | Director/Board Member | - | 23-01-15 |
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |